GlassScriptPhysician profile
Jennifer V Evans
NPI 1790335008
$1,673.29
in general payments reported to CMS, 2019-2025
19 companies · $314 in 2025
The $314 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,156 · 2024: $203 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,673.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $256.14 | 2023-2025 | Mitraclip, Cardiomems, Jot Dx |
| Amgen INC. | $250.07 | 2023-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $218.40 | 2023-2025 | |
| Abiomed | $166.33 | 2023-2024 | Impella |
| Janssen Pharmaceuticals, INC | $134.14 | 2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $126.50 | 2023-2025 | Lifevest |
| Novo Nordisk INC | $68.65 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $63.50 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $51.51 | 2023 | Verquvo |
| Kiniksa Pharmaceuticals, LTD. | $50.40 | 2023 | Arcalyst |
| Scpharmaceuticals INC. | $48.65 | 2023-2025 | |
| Csl Behring | $47.95 | 2023 | Kcentra |
| Actelion Pharmaceuticals US, INC. | $43.79 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Boston Scientific Corporation | $39.43 | 2025 | General - Crm_crm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.84 | 2023 | Jardiance |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $24.30 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $21.64 | 2025 | Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $16.45 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $14.60 | 2025 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.